Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 May 2026 The Chicago firm has added a partner with experience across patent litigation and strategic counselling for clients in the pharma, biotech, and advanced technology sectors.
28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.
27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.